期刊文献+

阿法替尼的合成工艺改进 被引量:2

Process Improvement on the Synthesis of Afatinib
下载PDF
导出
摘要 以2-氨基-4-氯苯甲酸为原料,经环合、硝化、氯代和胺化后,采用一锅两步法制得关键中间体4-[(3-氯-4-氟苯基)氨基]-6-硝基-7-[(S)-四氢呋喃-3-基氧基]-喹唑啉(4);4依次经还原、酰胺化、HWE反应合成阿法替尼,总收率55.7%,含量98%,其结构经~1H NMR和LC-MS确证。 The key intermediate, 4- [ ( 3-Chloro-4-fluorophenyl ) amino ] -6-nitro-7- L ( S ) -tetrahydrotU- ran-3-yloxy ] quinazolin (4) , was prepared from 2-amino-4-chlorobenzoic acid by cyclization, nitrification, chlorine generation and amination, then a "one-pot" process. Afatinib with total yield of 55.7% and purity of 98% was synthesized by reduction, amidation and HWE from 4. The structure was confirmed by 1H NMR and LC-MS.
作者 李文倩 宋国强 万屹东 高有军 冯筱晴 LI Wen-qian SONG Guo-qiang WAN Yi-dong GAO You-jun FENG Xiao-qing(School of Pharmaceutical Engineering and Life Sciences, Changzhou University, Changzhou 213164, China Changmao Biochemical Engineering Company Ltd. , Changzhou 213034, China College of Chemical Engineering, Nanjing Tech University, Nanjing 210009, China)
出处 《合成化学》 CAS CSCD 2017年第2期166-169,共4页 Chinese Journal of Synthetic Chemistry
基金 江苏省博士后科研资助计划(1501128B)
关键词 阿法替尼 药物合成 一锅法 工艺改进 Afatinib drug synthesis one-pot method process improvement
  • 相关文献

参考文献2

二级参考文献52

  • 1Jemal A,Murray T,Samuels A. Cancer statistics[J].CA:A Cancer Journal for Clinicians,2003,(01):5-26.doi:10.3322/canjclin.53.1.5.
  • 2Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anti-cancer agents[J].Drugs,2000,(01):1-14,41-42.doi:10.1517/14728220903540265.
  • 3Sibilia M,Kroismayr R,Lichtenberger BM. The epidermal growth factor receptor:from development to tumorigenesis[J].Differentiation,2007,(09):770-787.doi:10.1111/j.1432-0436.2007.00238.x.
  • 4Hirsch FR,Varella-Garcia M,Cappuzzo F. Predictive value of EGFR and HER2 over -expression in advanced non-small-cell lung cancer[J].Oncogene,2009,(Suppl1):S32-S37.
  • 5Kancha RK,von Bubnoff N,Peschel C. Functional analysis of epidermal growth factor receptor(EGFR)mutation and potential implications for EGFR targeted therapy[J].Clinical Cancer Research,2009,(2):460-467.doi:10.1158/1078-0432.CCR-08-1757.
  • 6Gazdar AF. Activating and resistance mutations of EGFR in non-small cell lung cancer:role in clinical response to EGFR tyrosine kinase inhibitors[J].Oncogene,2009,(suppl1):S24-S31.doi:10.1038/onc.2009.198.
  • 7Sibilia M,Kroismayr R,Lichtenberger BM. The epidermal growth factor receptor:from development to tumorigenesis[J].Differentiation,2007,(09):770-787.doi:10.1111/j.1432-0436.2007.00238.x.
  • 8Riely GJ,Pao W,Pham D. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib[J].Clinical Cancer Research,2006,(3 Pt 1):839-844.
  • 9Leidner RS,Fu P,Clifford B. Genetic abnormalities of the EGFR pathway in African American patients with non-small-cell lung cancer[J].Journal of Clinical Oncology,2009,(33):5620-5626.doi:10.1200/JCO.2009.23.1431.
  • 10Wissner A,Mansour TS. The development of HKI-272 and related compounds for the treatment of cancer[J].Archiv der Pharmazie,2008,(8):465-477.doi:10.1002/ardp.200800009.

共引文献15

同被引文献7

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部